As this report demonstrates, generic and biosimilar drugs continue to drive savings. The U.S. health care system, including patients, employers, and taxpayers, saved $373 billion in 2021 by using FDA-approved generic and biosimilar drugs. With 91% of Rx filled, but only 18% of how much the United States spends on drugs, these findings reinforce the critical importance of the generic and biosimilar industry to America’s patients. We encourage you to share the key findings with your social network.

#GRxBiosimsSavingsReport
STAY UP-TO-DATE

Find legislation in your area and send a message to your lawmaker to protect your access to affordable generic and biosimilar medicines.

• AAM Website: accessiblemeds.org
• AAM Action Center: takeaction.accessiblemeds.org

FOLLOW AAM ON SOCIAL MEDIA

/Followablemeds

FOLLOW THE BIOSIMILARS COUNCIL

/Followablemeds
2022 U.S. GENERIC AND BIOSIMILAR MEDICINES SAVINGS REPORT


TAKE ACTION

• Follow and share AAM’s Twitter posts especially those using the hashtag #GRxBiosimsSavingsReport
• Learn more about the issues on the AAM and Biosimilars Council advocacy pages
• Learn about advocacy campaigns in the AAM and Biosimilars Council Action Centers
MESSAGE

We encourage you to include the hashtag #GRxBiosimsSavingsReport in your tweets and tag @accessiblemeds and @biosimilarscouncil in all posts so we can share your message!

SOCIAL IMAGES

Click on each image to download. All images are accessible via Dropbox.

HASHTAGS

#GRxBiosimsSavingsReport
#PatientAccess
#Generics
#GenericDrugs
#GenericMedicines
#Biosimilars
#Biosimilar
#DrugPricing

If you need assistance, please contact AAM Senior Marketing Director Erica Klinger at: Erica.Klinger@accessiblemeds.org
New data from AAM's #GRxBiosimsSavingsReport shows that each #Medicare enrollee saved $2447 per year through the use of #generic and #biosimilar medicines—$119B for the system as a whole—in 2021 alone. Read more: https://bit.ly/AAMSavingsReport #patientaccess #drugpricing
AAM's #GRxBiosimsSavingsReport shows that in 2021, #generics and #biosimilars generated $97 billion in savings patients with #heartdisease, $60 billion for patients treating #mentalhealth, and $57 billion for persons living with #diabetes. View full report: https://bit.ly/AAMSavingsReport
91% of the 6.4 billion prescriptions filled in 2021 were for #generics and #biosimilars, however that 91% accounted for only 18% of spending on Rx medicines. View the full #GRxBiosimsSavingsReport report from @accessiblemeds: https://bit.ly/AAMSavingsReport #patientaccess #drugpricing

While spending on brand drugs increased in 2021, spending on #generic meds declined again, continuing a multi-year trend of #deflation for #generics of more than 5% annually, even while #inflation affects most other consumer goods. https://bit.ly/AAMSavingsReport #GRxBiosimsSavingsReport
The average copay for #generic drugs in 2021 was only $6.16, while the average copay for brand-name drugs was $56.12. View the full #GRxBiosimsSavingsReport report from AAM:
In 2021 alone, #generic & #biosimilar medicines generated a record $373 billion in savings for the U.S. healthcare system & nearly $2.6 trillion over the past decade. View report: https://bit.ly/AAMSavingsReport #generics #biosimilars #patientaccess #affordablemedicines #GRxBiosimsSavingsReport

In 2021 alone, #generic and #biosimilar medicines generated a record $373 billion in savings for the U.S. healthcare system & nearly $2.6 trillion over the past decade. View full report: https://bit.ly/AAMSavingsReport #generics #biosimilars #patientaccess #affordablemedicines #GRxBiosimsSavingsReport
New analysis from @accessiblemeds #GRxBiosimsSavingsReport shows that it takes 3 yrs. for new #genericmedicines to be covered by 50% of #Medicare Rx plans, meaning that #seniors pay more for longer than they should. Read more: https://bit.ly/AAMSavingsReport #patientaccess
Despite representing 91% of prescriptions dispensed in the US, #generic and #biosimilar medicines account for only 3% of total health care spending. Read more in @accessiblemeds 
On average, #biosimilar sales prices are more than 50% lower at launch than the price of its brand competitor. #Biosimilars saved $13B since 2015 ($7B in 2021 alone). Read more in @accessiblemeds @BiosimsCouncil #GRxBiosimsSavingsReport https://bit.ly/AAMSavingsReport

On average, #biosimilar sales prices are more than 50% lower at launch than the price of its brand competitor. #Biosimilars saved $13 billion since 2015 ($7 billion in 2021 alone). Read more in AAM’s #GRxBiosimsSavingsReport: https://bit.ly/AAMSavingsReport
Good news for #patientaccess from AAM's #GRxBiosimsSavingsReport: there are nearly 100 #biosimilar products under development, an almost 50% increase over the last 4 years. Read more: https://bit.ly/AAMSavingsReport #GRxBiosimsSavingsReport

Good news for #patientaccess from @accessiblemeds @biosimscouncil #GRxBiosimsSavingsReport: there are nearly 100 #biosimilar products under development, an almost 50% increase over the last 4 years. Read more: https://bit.ly/AAMSavingsReport #GRxBiosimsSavingsReport